DNA - NYSE

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc.

DNAยทNYSE

$8.73

-6.4%
HealthcareBiotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$570.28M
EPS-5.6400
P/E Ratio-1.55
Earnings Date08/06/2026
Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. Fair Value Envelope

DNA ยท NYSE

Our analysis suggests that DNA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.73, this represents a potential HIDDEN relative to our calculated worth for Ginkgo Bioworks Holdings, Inc..

HIDDEN
Intrinsic Value
Current Price: $8.73

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$18.7B
+ Cash & Equivalents$167.2M
Firm Value-$18.6B
- Debt$417.1M
Equity Value-$19.0B
/ Shares Outstanding54,646,293B
DCF Value-$348
OVERVALUED BY 4081%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$262.1M
-$401.6M
-$615.4M
-$943.0M
-$1.4B
-$2.2B
-$3.4B
-$5.2B
-$8.0B
-$12.2B
Maintenance CapEx
-$2.3M
-$3.6M
-$5.5M
-$8.5M
-$12.9M
-$19.8M
-$30.4M
-$46.6M
-$71.4M
-$109.4M
Owner Earnings
-$264.5M
-$405.2M
-$620.9M
-$951.4M
-$1.5B
-$2.2B
-$3.4B
-$5.2B
-$8.0B
-$12.3B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$244.9M
-$347.4M
-$492.9M
-$699.3M
-$992.2M
-$1.4B
-$2.0B
-$2.8B
-$4.0B
-$5.7B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your DNA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.